News archive
Showing 701 results
May 2026
-
Media Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto™ in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone in PSMAddition Deep PSA reduction higher in patients receiving Pluvicto… -
Media Release
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the…
April 2026
-
Media Release
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North… -
Media Release
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded… -
Media Release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,…
March 2026
-
Media Release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1… -
Media Release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx® data build on extensive body of… -
Media Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL‑17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty,…
February 2026
-
Media Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands… -
Media Release
New real‑world data reinforce earlier use of Pluvicto® before chemotherapy in metastatic castration-resistant prostate cancer
In the real-world, Pluvicto® showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI… -
Media Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment… -
Media Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a highly selective oral BTK inhibitor, was well-…